Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 8/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17197371 | 0.93 | SMN1; SMN2 (0.49) | KMT2ANPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL1697621 | 0.84 | MAPT (0.67) | KMT2ANPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL6377931 | 0.84 | KMT2A (0.57) | KMT2ANPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL17197367 | 0.83 | SMN1; SMN2 (0.52) | KMT2ANPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL22955262 | 0.83 | KMT2A (0.52) | KMT2ANPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL2964413 | 0.83 | KMT2A (0.52) | KMT2ANPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL657693 | 0.83 | CHEK1 (0.53) | KMT2ANPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL8789817 | 0.82 | SMN1; SMN2 (0.51) | KMT2ANPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL1961769 | 0.81 | CHRNB2 (0.57) | KMT2ANPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL1962847 | 0.80 | KMT2A (0.49) | KMT2ANPC1RAB9ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2507243-B1 | SPIROINDOLINONE PYRROLIDINES | HOFFMANN LA ROCHE (CH) | 2015-06-10 | — | — | EP | disclosed |
| EP-2507243-A1 | SPIROINDOLINONE PYRROLIDINES | F. Hoffmann-La Roche AG (CH) | 2012-10-10 | — | — | EP | disclosed |
| US-8088815-B2 | Spiroindolinone pyrrolidines | HOFFMAN-LA ROCHE INC. (US) | 2012-01-03 | — | — | US | disclosed |
| WO-2011067185-A1 | SPIROINDOLINONE PYRROLIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| US-20110130398-A1 | SPIROINDOLINONE PYRROLIDINES | BARTKOVITZ DAVID JOSEPH | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130398-A1 | SPIROINDOLINONE PYRROLIDINES | RPS4Y1, RB1, RPS4X | KMT2A 1856/4885NPC1 1194/4885RAB9A 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.